Estrogen receptor-positive, HER2-negative advanced breast cancer
Clinical trials for Estrogen receptor-positive, HER2-negative advanced breast cancer explained in plain language.
Never miss a new study
Get alerted when new Estrogen receptor-positive, HER2-negative advanced breast cancer trials appear
Sign up with your email to follow new studies for Estrogen receptor-positive, HER2-negative advanced breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill could outshine standard shot for tough breast cancer
Disease control OngoingThis Phase 3 study compares a new daily pill, giredestrant, against the standard shot fulvestrant, both given alongside a CDK4/6 inhibitor, in about 1,050 people with ER+/HER2- advanced breast cancer that has become resistant to prior hormone therapy. The goal is to see if girede…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill could offer hope for Hard-to-Treat breast cancer
Disease control OngoingThis Phase 3 trial is testing an experimental oral drug called ARV-471 against a standard injectable drug, fulvestrant, in people with a common type of advanced breast cancer (ER+/HER2-). The study includes 624 participants whose cancer has worsened after prior hormone-based trea…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug duo aims to stall advanced breast cancer
Disease control OngoingThis study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC